Why Pancreatic Cancer Is Hard to Beat
Pancreatic ductal adenocarcinoma is a very deadly cancer. Most of these tumors have a faulty gene called KRAS. The wrong KRAS helps the cancer grow fast and makes it tough to treat.
What the New Compounds Do
Scientists tested a group of chemicals named polyisoprenylated cysteinyl amide inhibitors (PCAIs). They were made to block the bad KRAS signals. In lab tests, the PCAIs were added to pancreatic‑cancer cells that carry KRAS mutations.
One Compound Stops Cancer Cells From Moving
Two PCAIs worked especially well. The team focused on the best one, called NSL‑YHJ‑2‑27. At a tiny dose (1 µM), this drug cut more than 90 % of the cells’ ability to crawl. That could help keep the cancer from spreading.
The drug also lowered the amount of small G‑proteins that the cells need to move. It changed the activity of genes that control tumor growth and messed up the cell’s skeleton (actin). The cancer cells became round and lost their speed.
Too Much Signal Can Kill the Cell
Usually, the MAPK and PI3K/AKT pathways help tumors grow. Surprisingly, PCAIs made these pathways go into overdrive. Too much activity can break normal cell functions and cause death.
Evidence showed that treated cells made more reactive oxygen, turned on caspase enzymes, raised the death‑promoting protein BAX, and went through apoptosis (programmed cell death).
Changes in Gene Activity
When the scientists looked at the cells’ genes, they saw big shifts. Genes that usually stop tumors became louder, while those that help cancer spread became quieter.
Testing in Tiny Tumor Models
Researchers also used three‑dimensional tumor spheroids, which act more like real tumors. The PCAIs broke the spheroids apart, stopped them from invading a gel that mimics tissue, and increased the number of dying cells.
Works on Many KRAS Mutations
Importantly, the drug did not only hit one KRAS variant. It affected several different KRAS mutations, which could solve a big problem with current KRAS‑targeted medicines that work for only one form.
Overall, the study shows that PCAIs can strongly fight pancreatic cancer cells by upsetting key signals, raising oxidative stress, and triggering cell death. More research is needed, but the results give hope for new treatments that work on many KRAS‑driven cancers.